Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import.

Rodriguez-Bravo V, Pippa R, Song WM, Carceles-Cordon M, Dominguez-Andres A, Fujiwara N, Woo J, Koh AP, Ertel A, Lokareddy RK, Cuesta-Dominguez A, Kim RS, Rodriguez-Fernandez I, Li P, Gordon R, Hirschfield H, Prats JM, Reddy EP, Fatatis A, Petrylak DP, Gomella L, Kelly WK, Lowe SW, Knudsen KE, Galsky MD, Cingolani G, Lujambio A, Hoshida Y, Domingo-Domenech J.

Cell. 2018 Aug 3. pii: S0092-8674(18)30909-7. doi: 10.1016/j.cell.2018.07.015. [Epub ahead of print]

PMID:
30100187
2.

Erratum: DNA sensing in senescence.

Ruiz de Galarreta M, Lujambio A.

Nat Cell Biol. 2017 Nov 29;19(12):1441. doi: 10.1038/ncb3644.

PMID:
29184173
3.

Cell type-specific pharmacological kinase inhibition for cancer chemoprevention.

Deshmukh M, Nakagawa S, Higashi T, Vincek A, Venkatesh A, Ruiz de Galarreta M, Koh AP, Goossens N, Hirschfield H, Bian CB, Fujiwara N, Ono A, Hoshida H, El-Abtah M, Ahmad NB, Lujambio A, Sanchez R, Fuchs BC, Poelstra K, Prakash J, Hoshida Y; Precision Liver Cancer Prevention Consortium.

Nanomedicine. 2018 Feb;14(2):317-325. doi: 10.1016/j.nano.2017.11.004. Epub 2017 Nov 20.

PMID:
29157977
4.

DNA sensing in senescence.

Ruiz de Galarreta M, Lujambio A.

Nat Cell Biol. 2017 Aug 31;19(9):1008-1009. doi: 10.1038/ncb3603. Erratum in: Nat Cell Biol. 2017 Nov 29;19(12 ):1441.

PMID:
28855731
5.

Therapeutic editing of hepatocyte genome in vivo.

Ruiz de Galarreta M, Lujambio A.

J Hepatol. 2017 Oct;67(4):818-828. doi: 10.1016/j.jhep.2017.05.012. Epub 2017 May 17. Review.

PMID:
28527665
6.

Strategies for HCC target discovery.

Molina-Sánchez P, Lujambio A.

Aging (Albany NY). 2017 Apr;9(4):1088-1089. doi: 10.18632/aging.101233. No abstract available.

7.

Integrin Beta 3 Regulates Cellular Senescence by Activating the TGF-β Pathway.

Rapisarda V, Borghesan M, Miguela V, Encheva V, Snijders AP, Lujambio A, O'Loghlen A.

Cell Rep. 2017 Mar 7;18(10):2480-2493. doi: 10.1016/j.celrep.2017.02.012.

8.

Histone Acetyltransferase Activity of MOF Is Required for MLL-AF9 Leukemogenesis.

Valerio DG, Xu H, Chen CW, Hoshii T, Eisold ME, Delaney C, Cusan M, Deshpande AJ, Huang CH, Lujambio A, Zheng YG, Zuber J, Pandita TK, Lowe SW, Armstrong SA.

Cancer Res. 2017 Apr 1;77(7):1753-1762. doi: 10.1158/0008-5472.CAN-16-2374. Epub 2017 Feb 15.

9.

USP39 Deubiquitinase Is Essential for KRAS Oncogene-driven Cancer.

Fraile JM, Manchado E, Lujambio A, Quesada V, Campos-Iglesias D, Webb TR, Lowe SW, López-Otín C, Freije JM.

J Biol Chem. 2017 Mar 10;292(10):4164-4175. doi: 10.1074/jbc.M116.762757. Epub 2017 Feb 1.

10.

Uncovering the role of USP54 in cancer.

Miguela V, Lujambio A.

Oncotarget. 2017 Feb 14;8(7):10765-10766. doi: 10.18632/oncotarget.14820. No abstract available.

11.

Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.

Bollard J, Miguela V, Ruiz de Galarreta M, Venkatesh A, Bian CB, Roberto MP, Tovar V, Sia D, Molina-Sánchez P, Nguyen CB, Nakagawa S, Llovet JM, Hoshida Y, Lujambio A.

Gut. 2017 Jul;66(7):1286-1296. doi: 10.1136/gutjnl-2016-312268. Epub 2016 Nov 14.

12.

An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.

Karoulia Z, Wu Y, Ahmed TA, Xin Q, Bollard J, Krepler C, Wu X, Zhang C, Bollag G, Herlyn M, Fagin JA, Lujambio A, Gavathiotis E, Poulikakos PI.

Cancer Cell. 2016 Sep 12;30(3):501-503. doi: 10.1016/j.ccell.2016.08.008. Epub 2016 Sep 12. No abstract available.

13.

IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.

Martinez-Quetglas I, Pinyol R, Dauch D, Torrecilla S, Tovar V, Moeini A, Alsinet C, Portela A, Rodriguez-Carunchio L, Solé M, Lujambio A, Villanueva A, Thung S, Esteller M, Zender L, Llovet JM.

Gastroenterology. 2016 Dec;151(6):1192-1205. doi: 10.1053/j.gastro.2016.09.001. Epub 2016 Sep 7.

14.

An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.

Karoulia Z, Wu Y, Ahmed TA, Xin Q, Bollard J, Krepler C, Wu X, Zhang C, Bollag G, Herlyn M, Fagin JA, Lujambio A, Gavathiotis E, Poulikakos PI.

Cancer Cell. 2016 Sep 12;30(3):485-498. doi: 10.1016/j.ccell.2016.06.024. Epub 2016 Aug 11. Erratum in: Cancer Cell. 2016 Sep 12;30(3):501-503.

15.

To clear, or not to clear (senescent cells)? That is the question.

Lujambio A.

Bioessays. 2016 Jul;38 Suppl 1:S56-64. doi: 10.1002/bies.201670910. Review.

PMID:
27417123
16.

Classical Physics and the Bounds of Quantum Correlations.

Frustaglia D, Baltanás JP, Velázquez-Ahumada MC, Fernández-Prieto A, Lujambio A, Losada V, Freire MJ, Cabello A.

Phys Rev Lett. 2016 Jun 24;116(25):250404. doi: 10.1103/PhysRevLett.116.250404. Epub 2016 Jun 24.

PMID:
27391707
17.

A combinatorial strategy for treating KRAS-mutant lung cancer.

Manchado E, Weissmueller S, Morris JP 4th, Chen CC, Wullenkord R, Lujambio A, de Stanchina E, Poirier JT, Gainor JF, Corcoran RB, Engelman JA, Rudin CM, Rosen N, Lowe SW.

Nature. 2016 Jun 30;534(7609):647-51. Epub 2016 Jun 22.

18.

The usual SASPects of liver cancer.

Lujambio A, Villanueva A.

Aging (Albany NY). 2015 Jun;7(6):348-9. No abstract available.

19.

A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer.

Vidal SJ, Rodriguez-Bravo V, Quinn SA, Rodriguez-Barrueco R, Lujambio A, Williams E, Sun X, de la Iglesia-Vicente J, Lee A, Readhead B, Chen X, Galsky M, Esteve B, Petrylak DP, Dudley JT, Rabadan R, Silva JM, Hoshida Y, Lowe SW, Cordon-Cardo C, Domingo-Domenech J.

Cancer Cell. 2015 Feb 9;27(2):223-39. doi: 10.1016/j.ccell.2014.11.013.

20.

CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma.

Huang CH, Lujambio A, Zuber J, Tschaharganeh DF, Doran MG, Evans MJ, Kitzing T, Zhu N, de Stanchina E, Sawyers CL, Armstrong SA, Lewis JS, Sherr CJ, Lowe SW.

Genes Dev. 2014 Aug 15;28(16):1800-14. doi: 10.1101/gad.244368.114.

21.

Splicing regulator SLU7 is essential for maintaining liver homeostasis.

Elizalde M, Urtasun R, Azkona M, Latasa MU, Goñi S, García-Irigoyen O, Uriarte I, Segura V, Collantes M, Di Scala M, Lujambio A, Prieto J, Ávila MA, Berasain C.

J Clin Invest. 2014 Jul;124(7):2909-20. doi: 10.1172/JCI74382. Epub 2014 May 27.

22.

Non-cell-autonomous tumor suppression by p53.

Lujambio A, Akkari L, Simon J, Grace D, Tschaharganeh DF, Bolden JE, Zhao Z, Thapar V, Joyce JA, Krizhanovsky V, Lowe SW.

Cell. 2013 Apr 11;153(2):449-60. doi: 10.1016/j.cell.2013.03.020. Epub 2013 Apr 4.

23.

Epigenetic disruption of cadherin-11 in human cancer metastasis.

Carmona FJ, Villanueva A, Vidal A, Muñoz C, Puertas S, Penin RM, Gomà M, Lujambio A, Piulats JM, Mesía R, Sánchez-Céspedes M, Manós M, Condom E, Eccles SA, Esteller M.

J Pathol. 2012 Oct;228(2):230-40. doi: 10.1002/path.4011. Epub 2012 Jul 26.

24.

The microcosmos of cancer.

Lujambio A, Lowe SW.

Nature. 2012 Feb 15;482(7385):347-55. doi: 10.1038/nature10888. Review.

25.

Bivalent histone modifications in stem cells poise miRNA loci for CpG island hypermethylation in human cancer.

Iliou MS, Lujambio A, Portela A, Brüstle O, Koch P, Andersson-Vincent PH, Sundström E, Hovatta O, Esteller M.

Epigenetics. 2011 Nov;6(11):1344-53. doi: 10.4161/epi.6.11.18021. Epub 2011 Nov 1.

PMID:
22048248
26.

Epigenetic activation of SOX11 in lymphoid neoplasms by histone modifications.

Vegliante MC, Royo C, Palomero J, Salaverria I, Balint B, Martín-Guerrero I, Agirre X, Lujambio A, Richter J, Xargay-Torrent S, Bea S, Hernandez L, Enjuanes A, Calasanz MJ, Rosenwald A, Ott G, Roman-Gomez J, Prosper F, Esteller M, Jares P, Siebert R, Campo E, Martín-Subero JI, Amador V.

PLoS One. 2011;6(6):e21382. doi: 10.1371/journal.pone.0021382. Epub 2011 Jun 27.

27.

CpG island hypermethylation-associated silencing of non-coding RNAs transcribed from ultraconserved regions in human cancer.

Lujambio A, Portela A, Liz J, Melo SA, Rossi S, Spizzo R, Croce CM, Calin GA, Esteller M.

Oncogene. 2010 Dec 2;29(48):6390-401. doi: 10.1038/onc.2010.361. Epub 2010 Aug 30.

28.

The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer.

Fernandez AF, Rosales C, Lopez-Nieva P, Graña O, Ballestar E, Ropero S, Espada J, Melo SA, Lujambio A, Fraga MF, Pino I, Javierre B, Carmona FJ, Acquadro F, Steenbergen RD, Snijders PJ, Meijer CJ, Pineau P, Dejean A, Lloveras B, Capella G, Quer J, Buti M, Esteban JI, Allende H, Rodriguez-Frias F, Castellsague X, Minarovits J, Ponce J, Capello D, Gaidano G, Cigudosa JC, Gomez-Lopez G, Pisano DG, Valencia A, Piris MA, Bosch FX, Cahir-McFarland E, Kieff E, Esteller M.

Genome Res. 2009 Mar;19(3):438-51. doi: 10.1101/gr.083550.108. Epub 2009 Feb 10.

29.

How epigenetics can explain human metastasis: a new role for microRNAs.

Lujambio A, Esteller M.

Cell Cycle. 2009 Feb 1;8(3):377-82. Epub 2009 Feb 1. Review.

PMID:
19177007
30.

A microRNA DNA methylation signature for human cancer metastasis.

Lujambio A, Calin GA, Villanueva A, Ropero S, Sánchez-Céspedes M, Blanco D, Montuenga LM, Rossi S, Nicoloso MS, Faller WJ, Gallagher WM, Eccles SA, Croce CM, Esteller M.

Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13556-61. doi: 10.1073/pnas.0803055105. Epub 2008 Sep 3.

31.

Molecular analysis of a multistep lung cancer model induced by chronic inflammation reveals epigenetic regulation of p16 and activation of the DNA damage response pathway.

Blanco D, Vicent S, Fraga MF, Fernandez-Garcia I, Freire J, Lujambio A, Esteller M, Ortiz-de-Solorzano C, Pio R, Lecanda F, Montuenga LM.

Neoplasia. 2007 Oct;9(10):840-52.

32.

CpG island hypermethylation of tumor suppressor microRNAs in human cancer.

Lujambio A, Esteller M.

Cell Cycle. 2007 Jun 15;6(12):1455-9. Epub 2007 May 4. Review.

PMID:
17581274
33.

Genetic unmasking of an epigenetically silenced microRNA in human cancer cells.

Lujambio A, Ropero S, Ballestar E, Fraga MF, Cerrato C, Setién F, Casado S, Suarez-Gauthier A, Sanchez-Cespedes M, Git A, Spiteri I, Das PP, Caldas C, Miska E, Esteller M.

Cancer Res. 2007 Feb 15;67(4):1424-9. Erratum in: Cancer Res. 2007 Apr 1;67(7):3492. Gitt, Anna [corrected to Git, Anna].

Supplemental Content

Loading ...
Support Center